GENEVA, Switzerland, March 31, 2011 - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced
today that Merck KGaA has entered into an agreement that broadens the scope
of the collaboration with Newron Pharmaceuticals S.p.A. ("Newron"), Milan,
Italy. The two companies are already collaborating on the development of
safinamide in Parkinson's disease.
Secure Solution to Accelerate Translational Research and Support Personalized Clinical Trials
